Literature DB >> 25913219

Are depressive symptomatology, self-efficacy, and perceived social support related to disability and quality of life in patients with chronic migraine associated to medication overuse? Data from a cross-sectional study.

Domenico D'Amico1, Licia Grazzi1, Gennaro Bussone1, Marcella Curone1, Paola Di Fiore1, Susanna Usai1, Matilde Leonardi2, Ambra Mara Giovannetti2, Silvia Schiavolin2, Alberto Raggi2.   

Abstract

BACKGROUND: Chronic migraine with medication overuse (CM-MO) impairs quality of life (QoL) and causes disability. Psychosocial variables such as depressive symptomatology, self-efficacy, and social support have been sparingly investigated, and their impact on disability and QoL is unknown.
METHODS: Patients with CM-MO under withdrawal were consecutively enrolled. Standardized measures of disability and QoL were used as outcomes; psychosocial (ie, mood state, self-efficacy, social support) and clinical (ie, headache frequency and intensity) variables were considered as associated variables. Associations between these variables, disability, and QoL were tested with Pearson's correlations. Hierarchical multiple regression was used to assess the cumulative contribution of psychosocial variables on disability and QoL variation when added to clinical variables.
RESULTS: One hundred ninety-four patients were enrolled; 82.5% were females and mean age was 43.9. Disability and QoL were moderately or little correlated to clinical and psychosocial variables. Models based on clinical variables explained 7.5-14.3% of disability and QoL variation, with pain intensity being the only significant predictor; when psychosocial variables were added, the explained variation increased to 21.5-35.2%, with depressive symptomatology always having independent predictive power and perceived social support having independent predictive power in the regression model over role-prevention component of QoL.
CONCLUSIONS: Adding information on psychosocial variables to headache features improved our ability to understand disability and QoL of CM-MO patients. We deem that the inclusion of psychosocial variables in standard evaluation protocols may contribute to the global assessment of CM-MO patients, and eventually to their success in reducing the personal and social impact of this condition. Future longitudinal studies are needed to confirm this hypothesis.
© 2015 American Headache Society.

Entities:  

Keywords:  chronic migraine with medication overuse; disability evaluation; health-related quality of life; mood; self-efficacy; social support

Mesh:

Year:  2015        PMID: 25913219     DOI: 10.1111/head.12534

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  10 in total

1.  Clinical and psychosocial features of frequent relapsers (FR) among patients with chronic migraine and medication overuse.

Authors:  Alberto Raggi; Licia Grazzi; Roberta Ayadi; Matilde Leonardi; Alberto Proietti; Silvia Schiavolin; Chiara Scaratti; Susanna Usai; Domenico D'Amico
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

2.  Health-related quality of life and associated factors in Chinese menstrual migraine patients: a cross-sectional study.

Authors:  Wenxiu Luo; Xing Cao; Jiayu Zhao; Jiaming Yang; Yu Cen; Jinlong He; Jing Luo; Yunling Zhong; Ying Luo; Xinyue Wang; Liqiu Yang; Xingyu Feng; Xiaoqing Pang; Jiazhu Zhang; Jiaming Luo
Journal:  BMC Womens Health       Date:  2022-05-15       Impact factor: 2.742

3.  Impact of depression and anxiety on burden and management of episodic and chronic headaches - a cross-sectional multicentre study in eight Austrian headache centres.

Authors:  Karin Zebenholzer; Anita Lechner; Gregor Broessner; Christian Lampl; Gernot Luthringshausen; Albert Wuschitz; Sonja-Maria Obmann; Klaus Berek; Christian Wöber
Journal:  J Headache Pain       Date:  2016-02-27       Impact factor: 7.277

4.  Factors Related to Social Support in Neurological and Mental Disorders.

Authors:  Kaloyan Kamenov; Maria Cabello; Francisco Félix Caballero; Alarcos Cieza; Carla Sabariego; Alberto Raggi; Marta Anczewska; Tuuli Pitkänen; Jose Luis Ayuso-Mateos
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

5.  Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up.

Authors:  Licia Grazzi; Emanuela Sansone; Alberto Raggi; Domenico D'Amico; Andrea De Giorgio; Matilde Leonardi; Laura De Torres; Francisco Salgado-García; Frank Andrasik
Journal:  J Headache Pain       Date:  2017-02-04       Impact factor: 7.277

6.  A Prospective Observational Cohort Study on Pharmacological Habitus, Headache-Related Disability and Psychological Profile in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylactic Treatment.

Authors:  Marialuisa Gandolfi; Valeria Donisi; Fabio Marchioretto; Simone Battista; Nicola Smania; Lidia Del Piccolo
Journal:  Toxins (Basel)       Date:  2019-08-29       Impact factor: 4.546

7.  From research to clinical practice: a systematic review of the implementation of psychological interventions for chronic headache in adults.

Authors:  Cinzia Perlini; Valeria Donisi; Lidia Del Piccolo
Journal:  BMC Health Serv Res       Date:  2020-05-25       Impact factor: 2.655

8.  Effects of Perceived Social Support, Depression and Anxiety Levels on Migraine.

Authors:  Ülkü Figen Demır; Oya Bozkurt
Journal:  Noro Psikiyatr Ars       Date:  2020-08-17       Impact factor: 1.339

9.  Loneliness and Migraine Self-Management: A Cross-Sectional Assessment.

Authors:  Jacob Z Lui; Nathan P Young; Jon O Ebbert; Jordan K Rosedahl; Lindsey M Philpot
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec

10.  Exploring Emotional Distress, Psychological Traits and Attitudes in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylaxis versus Withdrawal Treatment.

Authors:  Valeria Donisi; Maria Angela Mazzi; Marialuisa Gandolfi; Giuseppe Deledda; Fabio Marchioretto; Simone Battista; Sara Poli; Matteo Giansante; Eleonora Geccherle; Cinzia Perlini; Nicola Smania; Lidia Del Piccolo
Journal:  Toxins (Basel)       Date:  2020-09-08       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.